Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome
QNRXASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that its NETHERTON NOW awareness campaign has surpassed a major milestone, achieving more than one million video views and over 14 million impressions.
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
QNRXASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization.
Quoin Pharmaceuticals Receives FDA Clearance To Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
QNRXQuoin Pharmaceuticals Granted EMA Orphan Drug Designation For QRX003 In Netherton Syndrome With Potential 10 Years Of Market Exclusivity In Europe
QNRXWhy Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday
QNRXShares of Quoin Pharmaceuticals surged 47.5% Wednesday morning. The stock is higher following the release of promising initial data from its ongoing clinical study of QRX003.
Quoin Reports Early Data for Rare Skin Disease Treatment With No Adverse Events
QNRXQuoin Pharmaceuticals Q1 EPS $(6.50) Misses $(6.07) Estimate
QNRXA Peek at Quoin Pharmaceuticals's Future Earnings
QNRXQuoin Pharma Regains Nasdaq Compliance With Minimum Bid Price Requirement
QNRXTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
QNRXQuoin Reports Additional Clinical Data From Ongoing Investigator Pediatric Netherton Syndrome Study; Reveals Continued Clear Visual Evidence Of Almost Completely Healed Skin After 6 Weeks Treatment
QNRXQuoin Pharmaceuticals Filed US Patent Application For Novel Topical Formulations For Skin Diseases, Including Netherton Syndrome, Quoin's Lead Product, QRX003, Is Currently Being Tested In Four Netherton Syndrome Clinical Trials
QNRXQuoin Pharmaceuticals FY 2024 GAAP EPS $(1.91) Beats $(2.10) Estimate, Quoin Had Approximately $14.1M In Cash, Cash Equivalents And Marketable That Is Expected To Fund The Company's Operations Into Q2 Of 2026
QNRXQuoin Files US And International Patent Applications For Novel Topical Rapamycin Formulations As Potential Treatments For Rare Disease Indications
QNRXQuoin Pharmaceuticals Announces Whole Body' Data From Ongoing Pediatric Netherton Syndrome Study; Says Both Key Clinical Endpoints Demonstrated Significant Clinical Improvements From Baseline After Two Weeks Of Treatment With QRX003
QNRXQuoin Pharmaceuticals Launches First Episode In Its Living with Netherton Video Series
QNRXQuoin Pharmaceuticals Reports Interim Clinical Data From Ongoing Investigator Pediatric Netherton Syndrome Clinical Study
QNRXQuoin Pharmaceuticals Prices $6.8M Public Offering Of 15,111,110 American Depository Shares And Series F Warrants At $0.45 Per ADS And Series F And Series G Warrants
QNRXQuoin Pharmaceuticals Receives FDA Clearance To Initiate A New QRX003 Netherton Syndrome Clinical Study
QNRXQuoin Pharmaceuticals Initiates Clinical Testing Of Lead Product In Pediatric Netherton Syndrome Patient At A Children's Health Ireland In Dublin
QNRXQNRX: FDA Clearance To Move QRX003 Clinical Testing Forward; Positive Implications
QNRXBy M. Marin
NASDAQ:QNRX
READ THE FULL QNRX RESEARCH REPORT
